Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM C HUANG

Allopathic & Osteopathic Physicians Urology

NPI
1235274101
CMS profile
192305
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,467.45

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $4,800.00 1
Travel and Lodging $2,003.07 3
Food and Beverage $1,664.38 32

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
UroGen Pharma, Inc. $6,841.38 23
Telix Pharmaceuticals $1,278.87 1
ABBVIE INC. $217.16 9
Intuitive Surgical, Inc. $107.21 2
Medtronic, Inc. $22.83 1

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM C HUANG

NPI 1235274101 · CMS profile ID 192305

Allopathic & Osteopathic Physicians / Urology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235274101?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM C HUANG, NPI 1235274101, CMS profile ID 192305. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235274101?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WILLIAM C HUANG, NPI 1235274101, CMS profile ID 192305. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235274101?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WILLIAM C HUANG, NPI 1235274101, CMS profile ID 192305, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1235274101?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $8,467.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UroGen Pharma, Inc. $30.9912/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038603217 CMS
UroGen Pharma, Inc. $23.1112/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038627745 CMS
ABBVIE INC. $23.3812/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511197 CMS
UroGen Pharma, Inc. $35.9412/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038592899 CMS
UroGen Pharma, Inc. $551.2012/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038605267 CMS
UroGen Pharma, Inc. $173.0012/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038605275 CMS
UroGen Pharma, Inc. $234.9312/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038605283 CMS
UroGen Pharma, Inc. $4,800.0012/01/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038610471 CMS
UroGen Pharma, Inc. $34.2011/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038613193 CMS
UroGen Pharma, Inc. $1.5811/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038613519 CMS
UroGen Pharma, Inc. $23.9511/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038609267 CMS
UroGen Pharma, Inc. $36.9811/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038600653 CMS
UroGen Pharma, Inc. $40.6311/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038610159 CMS
UroGen Pharma, Inc. $23.1110/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038613857 CMS
UroGen Pharma, Inc. $28.0110/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038622041 CMS
UroGen Pharma, Inc. $1.7310/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038599381 CMS
ABBVIE INC. $27.3710/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511195 CMS
ABBVIE INC. $23.2709/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511193 CMS
UroGen Pharma, Inc. $27.1509/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038590219 CMS
ABBVIE INC. $24.7008/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511191 CMS
UroGen Pharma, Inc. $161.7108/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038627355 CMS
ABBVIE INC. $26.1008/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511189 CMS
ABBVIE INC. $25.4407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511187 CMS
Intuitive Surgical, Inc. $38.7907/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055816147 CMS
ABBVIE INC. $17.0206/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511185 CMS
UroGen Pharma, Inc. $21.5806/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038597227 CMS
ABBVIE INC. $19.2806/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511183 CMS
ABBVIE INC. $30.6005/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997511181 CMS
UroGen Pharma, Inc. $145.0005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038620839 CMS
UroGen Pharma, Inc. $23.8705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038623761 CMS
Medtronic, Inc. $22.8305/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019325883 CMS
UroGen Pharma, Inc. $153.1504/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038590533 CMS
Telix Pharmaceuticals $1,278.8704/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005796193 CMS
UroGen Pharma, Inc. $163.4704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038614339 CMS
UroGen Pharma, Inc. $106.0903/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038597271 CMS
Intuitive Surgical, Inc. $68.4201/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055483767 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,731.05 22
PY2020 $26.34 1
PY2021 $5,350.33 4
PY2022 $4,360.83 6
PY2023 $8,467.45 36
PY2024 $6,579.56 28
PY2025 $25,714.00 25

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,271.65 15
PY2024 Principal investigator $357,575.61 34
PY2023 Principal investigator $1,101,265.37 95
PY2022 Principal investigator $1,165,009.64 43
PY2021 Principal investigator $831,232.81 89
PY2020 Principal investigator $70,992.92 9
PY2019 Principal investigator $6,627.63 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $115,231.27 12/31/2024 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 No dispute reported 06/30/2026 1136412422
Principal investigator 1 Merck Sharp & Dohme LLC $78,308.51 12/31/2024 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 No dispute reported 06/30/2026 1136413671
Principal investigator 1 UROGEN PHARMA, INC. $451.68 12/31/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1137930639
Principal investigator 1 UROGEN PHARMA, INC. $451.68 12/31/2024 Non-covered Recipient Entity
NYU GROSSMAN SCHOOL OF MEDICINE
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1137930723
Principal investigator 1 Merck Sharp & Dohme LLC $131,767.30 12/27/2024 Non-covered Recipient Entity
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 No dispute reported 06/30/2026 1136413667
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930063
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930068
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930072
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930102
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930111
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930158
Principal investigator 1 UROGEN PHARMA, INC. $29.25 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930162
Principal investigator 1 UROGEN PHARMA, INC. $29.25 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930166
Principal investigator 1 UROGEN PHARMA, INC. $29.25 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930171
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930175
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930221
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930225
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930230
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930243
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930255
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930259
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930263
Principal investigator 1 UROGEN PHARMA, INC. $39.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930268
Principal investigator 1 UROGEN PHARMA, INC. $1,000.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930462
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930466
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930487
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930491
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930495
Principal investigator 1 UROGEN PHARMA, INC. $95.00 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930500
Principal investigator 1 UROGEN PHARMA, INC. $29.25 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930504
Principal investigator 1 UROGEN PHARMA, INC. $29.25 12/13/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1137930508
Principal investigator 1 UROGEN PHARMA, INC. $526.96 07/31/2024 Non-covered Recipient Entity
NYU GROSSMAN SCHOOL OF MEDICINE
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1137930361
Principal investigator 1 UROGEN PHARMA, INC. $526.96 07/31/2024 Non-covered Recipient Entity
MANHATTAN MEDICAL RESEARCH PRACTICE, PLLC
BL011 - A PHASE 3 SINGLE-ARM STUDY OF UGN -102 FOR TREATMENT OF LOW GRADE INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER (ENVISION) No dispute reported 06/30/2026 1137930567
Principal investigator 1 Photocure Inc $27,825.00 02/21/2024 Non-covered Recipient Entity
NYU GROSSMAN SCHOOL OF MEDICINE
Blue Light Cystoscopy With Cysview Registry No dispute reported 06/30/2026 1119802388